Pfizer’s 2026 Guidance Misses, Boosting Bearish Sentiment and Uncertain Growth Outlook
Pfizer’s 2026 earnings miss sparks a sharp shift to “hold” and rising bearish sentiment, as price‑control pressures and safety concerns threaten the pharma giant’s growth legacy.
3 minutes to read